News & Events about Wave Life Sciences Ltd.
Globe Newswire
3 months ago
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference ...
Globe Newswire
5 months ago
53% mean exon skipping and PN chemistry improved pharmacology of WVE-N531 compared with Waves first-generation DMD program demonstrated high muscle concentrations with a mean of 42 micrograms/gram WVE-N531 appeared safe and well tolerated Third Wave clinical trial evaluating a PN chemistry-...
Globe Newswire
7 months ago
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive ...
Globe Newswire
8 months ago
WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both lung and liver phenotypes IND-enabling activities for WVE-006 are underway and Wave expects to submit clinical ...
Globe Newswire
8 months ago
Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentationCAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments ...